{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:35:16Z","timestamp":1791408916450,"version":"4.3.3"},"reference-count":55,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The p53 protein is a tumor-suppressing transcription factor that is critical in tumorigenesis. While TP53 mutations are rare in differentiated thyroid cancer (DTC), they are significantly more common in anaplastic thyroid cancer (ATC). This study presents original results and a meta-analysis reevaluating the prognostic value of TP53 mutations in thyroid cancer, including surrogate markers such as immunohistochemical p53 expression and serum p53-Abs levels. TP53 mutations were analyzed using SSSP and direct sequencing in a DTC group (15 patients), an ATC group (3 patients), and a control group (25 patients). The immunohistochemical p53 expression was assessed in tissue samples. A meta-analysis of 14 eligible studies identified through the PubMed, Scopus, Google Scholar, and Cochrane databases was conducted. Our results showed TP53 mutations in all ATC cases, 6.67% of DTC cases (1 out of 15), and none in the control group. Immunohistochemical p53 overexpression was observed in 4 out of 15 DTC (26.67%) and all ATC cases but absent in controls. A meta-analysis confirmed that TP53 mutations are significantly more frequent in ATC than controls (OR 8.95; 95% CI: 1.36\u201358.70; p = 0.02) but not in DTC vs. controls (OR 1.87; 95% CI: 0.53\u20136.58; p = 0.33). p53 overexpression was significantly higher in both DTC and ATC vs. controls (OR 7.99; 95% CI: 5.11\u201312.51; p &lt; 0.01 and OR 64.37; 95% CI: 27.28\u2013151.89; p &lt; 0.01, respectively). The serum p53-Abs positivity was also elevated in patients with PTC vs. controls (OR 2.07; 95% CI: 1.24\u20133.47; p &lt; 0.01). TP53 mutations are frequent events in the pathogenesis of ATC. In DTC, further prospective studies are needed to determine the prognostic value of TP53 mutations and related surrogate markers (immunohistochemical p53 expression, p53-Abs positivity).<\/jats:p>","DOI":"10.3390\/ijms26031035","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T03:54:27Z","timestamp":1737950067000},"page":"1035","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Rationale for Testing TP53 Mutations in Thyroid Cancer\u2014Original Data and Meta-Analysis"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2386-4795","authenticated-orcid":false,"given":"Katarzyna","family":"Lacka","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5381-3211","authenticated-orcid":false,"given":"Adam","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3371-6154","authenticated-orcid":false,"given":"Piotr","family":"Tyburski","sequence":"additional","affiliation":[{"name":"Student Scientific Society, Poznan University of Medical Sciences, 60-806 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Manuszewska-Jopek","sequence":"additional","affiliation":[{"name":"Outpatients Unit for Endocrine Diseases, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Majewski","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathomorphology, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1811-2583","authenticated-orcid":false,"given":"Barbara","family":"Wi\u0119ckowska","sequence":"additional","affiliation":[{"name":"Department of Computer Science and Statistics, Poznan University of Medical Science, 60-806 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e140923221042","DOI":"10.2174\/1874467217666230914090621","article-title":"Targeting Mutant-p53 for Cancer Treatment: Are We There Yet?","volume":"17","author":"Lim","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","article-title":"Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 Mutations in Cancer","volume":"15","author":"Muller","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jmcb\/mjz026","article-title":"The Many Faces of p53: Something for Everyone","volume":"11","author":"Levine","year":"2019","journal-title":"J. Mol. Cell Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1007\/s12094-024-03533-1","article-title":"The Clinical Features and Prognostic Implications of the Co-Mutated TP53 Gene in Advanced Non-Small Cell Lung Cancer","volume":"26","author":"Bai","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in Cancer: From Molecular Mechanism to Therapeutic Modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/jmcb\/mjaa040","article-title":"Gain-of-Function Mutant p53 in Cancer Progression and Therapy","volume":"12","author":"Zhang","year":"2020","journal-title":"J. Mol. Cell Biol."},{"key":"ref_8","first-page":"87","article-title":"Rola procesu apoptozy w etiopatogenezie autoimmunologicznego zapalenia tarczycy [The Role of Apoptosis in the Etiopathogenesis of Autoimmune Thyroiditis]","volume":"32","author":"Lacka","year":"2012","journal-title":"Pol. Merkur Lekarski."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1158\/1055-9965.EPI-21-1440","article-title":"Epidemiology of Thyroid Cancer","volume":"31","author":"Kitahara","year":"2022","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.21073","article-title":"Evidence That One Subset of Anaplastic Thyroid Carcinomas Are Derived from Papillary Carcinomas Due to BRAF and p53 Mutations","volume":"103","author":"Quiros","year":"2005","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Romei, C., and Elisei, R. (2021). A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041726"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5603\/ep.97567","article-title":"p53-Associated miRNAs Repress lncRNA ZFAS1 to Retard the Proliferation of Papillary Thyroid Carcinoma","volume":"75","author":"Wang","year":"2024","journal-title":"Endokrynol. Pol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1210\/clinem\/dgaa950","article-title":"DNA Methylation Haplotype Block Markers Efficiently Discriminate Follicular Thyroid Carcinoma from Follicular Adenoma","volume":"106","author":"Zhang","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00109-008-0322-6","article-title":"Analysis of Human MDM4 Variants in Papillary Thyroid Carcinomas Reveals New Potential Markers of Cancer Properties","volume":"86","author":"Prodosmo","year":"2008","journal-title":"J. Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1172\/JCI116168","article-title":"High Prevalence of Mutations of the p53 Gene in Poorly Differentiated Human Thyroid Carcinomas","volume":"91","author":"Fagin","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1530\/eje.0.1340177","article-title":"Low Frequency of p53 Mutations in Human Thyroid Tumors; p53 and Ras Mutation in Two Out of Fifty-Six Thyroid Tumors","volume":"134","author":"Salvatore","year":"1996","journal-title":"Eur. J. Endocrinol."},{"key":"ref_17","first-page":"1054","article-title":"p53 Mutations in All Stages of Thyroid Carcinomas","volume":"77","author":"Zou","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"846584","DOI":"10.1155\/2013\/846584","article-title":"P53 and Expression of Immunological Markers May Identify Early Stage Thyroid Tumors","volume":"2013","author":"Marcello","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1159\/000481640","article-title":"Wild-Type P53 Induces Sodium\/Iodide Symporter Expression Allowing Radioiodide Therapy in Anaplastic Thyroid Cancer","volume":"43","author":"Liu","year":"2017","journal-title":"Cell Physiol. Biochem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/PAT.0b013e3283486178","article-title":"BRAF, p53, and SOX2 in Anaplastic Thyroid Carcinoma: Evidence for Multistep Carcinogenesis","volume":"43","author":"Gauchotte","year":"2011","journal-title":"Pathology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/bjc.1996.528","article-title":"Expression of p21 (WAF1\/CIP1) Protein in Clinical Thyroid Tissues","volume":"74","author":"Ito","year":"1996","journal-title":"Br. J. Cancer."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF02739971","article-title":"Possible Relation of p53 and MDM2 Oncoprotein Expression in Thyroid Carcinoma: A Molecular-Pathological and Immunohistochemical Study on Paraffin-Embedded Tissue","volume":"7","author":"Schmid","year":"1996","journal-title":"Endocr. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0304-3835(96)04196-1","article-title":"p53 Gene Mutation in Thyroid Carcinoma","volume":"103","author":"Ho","year":"1996","journal-title":"Cancer Lett."},{"key":"ref_24","first-page":"21327","article-title":"Clinical Significance of Preoperative Detection of Serum p53 Antibodies and BRAF(V600E) Mutation in Patients with Papillary Thyroid Carcinoma","volume":"8","author":"Fu","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12149-013-0783-8","article-title":"p53 Antibody: Is It an Indicator of Dedifferentiated Thyroid Cancer?","volume":"28","author":"Hasbek","year":"2014","journal-title":"Ann. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12020-014-0243-9","article-title":"Detection of Serum p53 Antibodies from Chinese Patients with Papillary Thyroid Carcinoma Using Phage-SP-ELISA: Correlation with Clinical Parameters","volume":"47","author":"Pan","year":"2014","journal-title":"Endocrine"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chiang, Y.T., Chien, Y.C., Lin, Y.H., Wu, H.H., Lee, D.F., and Yu, Y.L. (2021). The Function of the Mutant p53-R175H in Cancer. Cancers, 13.","DOI":"10.3390\/cancers13164088"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"102226","DOI":"10.1016\/j.clgc.2024.102226","article-title":"Evaluation of the Prognostic Role of TP53 Gene Mutations in Prostate Cancer Outcome: A Systematic Review and Meta-Analysis","volume":"22","author":"Maddah","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000526174","article-title":"The Prognostic Value of TP53 Mutations in Adult Acute Myeloid Leukemia: A Meta-Analysis","volume":"50","author":"Qin","year":"2022","journal-title":"Transfus. Med. Hemother."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Basyuni, S., Nugent, G., Ferro, A., Barker, E., Reddin, I., Jones, O., Lechner, M., O\u2019Leary, B., Jones, T., and Masterson, L. (2022). Value of p53 Sequencing in the Prognostication of Head and Neck Cancer: A Systematic Review and Meta-Analysis. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-25291-2"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"104018","DOI":"10.1016\/j.critrevonc.2023.104018","article-title":"The Prognostic Role of p53 Mutations in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis","volume":"186","author":"Ottaiano","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and Transcriptomic Hallmarks of Poorly Differentiated and Anaplastic Thyroid Cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"eabf3657","DOI":"10.1126\/sciadv.abf3657","article-title":"Characterizing Dedifferentiation of Thyroid Cancer by Integrated Analysis","volume":"7","author":"Luo","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/1097-0215(20010720)95:4<232::AID-IJC1040>3.0.CO;2-5","article-title":"Heterogeneous Distribution of P53 Immunoreactivity in Human Lung Adenocarcinoma Correlates with MDM2 Protein Expression, Rather than with P53 Gene Mutation","volume":"95","author":"Koga","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00428-023-03676-6","article-title":"Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas","volume":"485","author":"Noordenbos","year":"2024","journal-title":"Virchows Arch."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00428-024-03897-3","article-title":"Aberrant p53 Immunostaining Patterns in Breast Carcinoma of No Special Type Strongly Correlate with Presence and Type of TP53 Mutations","volume":"485","author":"Armbruster","year":"2024","journal-title":"Virchows Arch."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41379-022-01102-x","article-title":"p53 immunohistochemistry in endometrial cancer: Clinical and molecular correlates in the PORTEC-3 trial","volume":"35","author":"Vermij","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Osakabe, M., Yamada, N., Sugimoto, R., Uesugi, N., Nakao, E., Honda, M., Yanagawa, N., and Sugai, T. (2024). The Pattern-Based Interpretation of p53 Immunohistochemical Expression as a Surrogate Marker for TP53 Mutations in Colorectal Cancer. Virchows Arch.","DOI":"10.1007\/s00428-024-03790-z"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13000-022-01273-w","article-title":"p53 Immunostaining Pattern Is a Useful Surrogate Marker for TP53 Gene Mutations","volume":"17","author":"Sung","year":"2022","journal-title":"Diagn. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cjp2.53","article-title":"Optimized p53 Immunohistochemistry as an Accurate Predictor of TP53 Mutation in Ovarian Carcinoma","volume":"2","author":"Piskorz","year":"2016","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1007\/s00268-008-9756-9","article-title":"Clinical Significance of P53 Protein Expression in Papillary Thyroid Carcinoma","volume":"32","author":"Morita","year":"2008","journal-title":"World J. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.30699\/ijp.2023.553716.2897","article-title":"YAP1 and P53 Expression in Papillary Thyroid Carcinoma","volume":"18","author":"Abdelhafez","year":"2023","journal-title":"Iran. J. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"151766","DOI":"10.1016\/j.anndiagpath.2021.151766","article-title":"Clinical Utility of the Immunohistochemical Co-Expression of p53 and MDM2 in Thyroid Follicular Lesions","volume":"53","author":"Martins","year":"2021","journal-title":"Ann. Diagn Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1440-1827.2001.01159.x","article-title":"Overexpression of p53 Protein and MDM2 in Papillary Carcinomas of the Thyroid: Correlations with Clinicopathologic Features","volume":"51","author":"Horie","year":"2001","journal-title":"Pathol. Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PAS.0000000000002153","article-title":"Divergent Lineage Markers in Anaplastic Thyroid Carcinoma","volume":"48","author":"Mneimneh","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Sobhani, N., Roviello, G., D\u2019Angelo, A., Roudi, R., Neeli, P.K., and Generali, D. (2021). p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis. Molecules, 26.","DOI":"10.20944\/preprints202109.0348.v1"},{"key":"ref_47","first-page":"1777","article-title":"p53 Antibodies in the Sera of Patients with Various Types of Cancer: A Review","volume":"60","author":"Soussi","year":"2000","journal-title":"Cancer Res."},{"key":"ref_48","first-page":"477","article-title":"The Role of the p53 Protein in the Prediction of Clinical Resistance to Cytostatic Treatment in Cancer Patients","volume":"29","author":"Mudry","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41420-019-0207-1","article-title":"Autoantibodies as Diagnostic Biomarkers for Lung Cancer: A Systematic Review","volume":"5","author":"Yang","year":"2019","journal-title":"Cell Death Discov."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ags3.12757","article-title":"Serum NY-ESO-1 and p53 Antibodies as Useful Tumor Markers in Gastric Cancer","volume":"8","author":"Kawada","year":"2023","journal-title":"Ann. Gastroenterol. Surg."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"949098","DOI":"10.3389\/fonc.2022.949098","article-title":"Thyroid Cancer Harboring PTEN and TP53 Mutations: A Peculiar Molecular and Clinical Case Report","volume":"12","author":"Colombo","year":"2022","journal-title":"Front Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"G\u0105sior-Perczak, D., Kowalik, A., Kopczy\u0144ski, J., Macek, P., Niemyska, K., Walczyk, A., Gruszczy\u0144ski, K., Sio\u0142ek, M., Dr\u00f3\u017cd\u017c, T., and Kosowski, M. (2024). Relationship between the Expression of CHK2 and p53 in Tumor Tissue and the Course of Papillary Thyroid Cancer in Patients with CHEK2 Germline Mutations. Cancers, 16.","DOI":"10.3390\/cancers16040815"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Vrinceanu, D., Dumitru, M., Marinescu, A., Serboiu, C., Musat, G., Radulescu, M., Popa-Cherecheanu, M., Ciornei, C., and Manole, F. (2024). Management of Giant Thyroid Tumors in Patients with Multiple Comorbidities in a Tertiary Head and Neck Surgery Center. Biomedicines, 12.","DOI":"10.3390\/biomedicines12102204"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","article-title":"Translating p53-Based Therapies for Cancer into the Clinic","volume":"24","author":"Peuget","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-024-01566-1","article-title":"Remodeling of Anti-Tumor Immunity with Antibodies Targeting a p53 Mutant","volume":"17","author":"Chai","year":"2024","journal-title":"J. Hematol. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1035\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:36:08Z","timestamp":1759919768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ijms26031035"],"URL":"https:\/\/doi.org\/10.3390\/ijms26031035","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]}}}